Diabetes research and clinical practice · 2026
The effect of rapid improvement of blood glucose level on diabetic neuropathy in Korean people with diabetes mellitus.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choe Hun Jee, Koo Bo Kyung, Hong Yoon-Ho, Kim Nam Hoon, Moon Jun Sung, Lee Yong-Ho, Cho Ho Chan, Kwak Soo Heon, Lim Soo, Kim Dong-Lim, Kim Tae Ho, Kim Sin Gon, Moon Min Kyong
Аннотация
AIMS: Treatment-induced neuropathy of diabetes is a well-documented complication of rapid glycemic improvement, yet its frequency and severity in guideline-concordant clinical settings remain uncertain.
METHODS: This prospective observational study assessed short-term changes in neuropathy and autonomic function in two Korean cohorts undergoing rapid glycemic control: the Boramae Neuropathy cohort (n = 71, ≥2% HbA1c reduction over 12 weeks) and the TRIPLE-AXEL cohort (n = 79 newly diagnosed, drug-naïve type 2 diabetes patients with ≥ 2% HbA1c reduction). Measures included Neuropathy Total Symptom Score-6 (NTSS-6), Michigan Neuropathy Screening Instrument (MNSI), and Composite Autonomic Symptom Score-31 (COMPASS-31).
RESULTS: Despite marked HbA1c reductions, neuropathy indices did not worsen. In the Boramae cohort, HbA1c decreased from 11.3 ± 1.4% to 6.9 ± 0.8%, NTSS-6 remained stable, and abnormal COMPASS-31 prevalence fell from 36.6% to 29.6%. In TRIPLE-AXEL, HbA1c decreased from 9.5 ± 0.8% to 6.4 ± 0.6%, with no increases in MNSI or COMPASS-31 scores and reduced abnormal COMPASS-31 prevalence (6.3% to 1.3%). A small subset in the Boramae cohort (8.5%) developed abnormal COMPASS-31 scores, mainly orthostatic symptoms, without increased neuropathic pain.
CONCLUSION: Rapid glycemic improvement was not associated with clinically meaningful short-term worsening of neuropathy. Mild, domain-specific autonomic changes occurred in a minority without painful neuropathy, supporting the safety of intensive glycemic control with appropriate screening.
METHODS: This prospective observational study assessed short-term changes in neuropathy and autonomic function in two Korean cohorts undergoing rapid glycemic control: the Boramae Neuropathy cohort (n = 71, ≥2% HbA1c reduction over 12 weeks) and the TRIPLE-AXEL cohort (n = 79 newly diagnosed, drug-naïve type 2 diabetes patients with ≥ 2% HbA1c reduction). Measures included Neuropathy Total Symptom Score-6 (NTSS-6), Michigan Neuropathy Screening Instrument (MNSI), and Composite Autonomic Symptom Score-31 (COMPASS-31).
RESULTS: Despite marked HbA1c reductions, neuropathy indices did not worsen. In the Boramae cohort, HbA1c decreased from 11.3 ± 1.4% to 6.9 ± 0.8%, NTSS-6 remained stable, and abnormal COMPASS-31 prevalence fell from 36.6% to 29.6%. In TRIPLE-AXEL, HbA1c decreased from 9.5 ± 0.8% to 6.4 ± 0.6%, with no increases in MNSI or COMPASS-31 scores and reduced abnormal COMPASS-31 prevalence (6.3% to 1.3%). A small subset in the Boramae cohort (8.5%) developed abnormal COMPASS-31 scores, mainly orthostatic symptoms, without increased neuropathic pain.
CONCLUSION: Rapid glycemic improvement was not associated with clinically meaningful short-term worsening of neuropathy. Mild, domain-specific autonomic changes occurred in a minority without painful neuropathy, supporting the safety of intensive glycemic control with appropriate screening.